Advanced Cell Technology, a biotechnology company applying human embryonic stem cell technology in the emerging field of regenerative medicine. Currently our research medicine and development efforts focus primarily on developing human embryonic stem cells and embryonic stem cell derived products in therapeutically useful quantities; however, early research efforts at ACT focused on animals and agriculture. ACT was incorporated in Delaware in 1994 as a subsidiary of Avian Farms, Inc., a former poultry genetics Company based in Maine. In 1999, ACT Group was formed to effect the buy-out of approximately 80% of the equity interests in ACT from Avian Farms. ACT operated under the control of ACT Group from its acquisition in 1999 through the recent completion date of the Company’s reverse merger. As a result of the reverse merger, the Company is now publicly traded under the ticker “ACTH” on the Over The Counter Bulletin Board exchange.